

John R Wingard

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1186630/john-r-wingard-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

461
papers

43,876
citations

83
h-index

204
g-index

552
ext. papers

49,081
ext. citations

5.1
avg. IF

6.73
L-index

#	Paper	IF	Citations
461	Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.. <i>Lancet Haematology</i> , 2022 , 9, e374-e384	14.6	0
460	The Impact of Pre-Apheresis Health Related Quality of Life on Peripheral Blood Progenitor Cell Yield and Donor's Health and Outcome: Secondary Analysis of Rdsafe and BMT CTN 0201. <i>Blood</i> , 2021 , 138, 1772-1772	2.2	
459	Distress, Health-Related Quality of Life (HQOL) and Confidence in Survivorship Information (CSI) in Older (≥80 Years) Hematopoietic Cell Transplant (HCT) Patients. <i>Blood</i> , 2021 , 138, 426-426	2.2	
458	Cancer and Treatment Distress (CTXD) and Confidence in Survivorship Information (CSI) Trends in Older (≥80 Years) Allogeneic Hematopoietic Cell Transplantation (AlloHCT) Survivors. <i>Blood</i> , 2021 , 138, 4123-4123	2.2	
457	Self-Efficacy for Symptom Management in Long-Term Adult Hematopoietic Stem Cell Survivors. <i>Blood</i> , 2021 , 138, 3932-3932	2.2	
456	A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients. <i>EClinicalMedicine</i> , 2021 , 33, 100787	11.3	2
455	Aspergillus Polymerase Chain Reaction-An Update on Technical Recommendations, Clinical Applications, and Justification for Inclusion in the Second Revision of the EORTC/MSGERC Definitions of Invasive Fungal Disease. <i>Clinical Infectious Diseases</i> , 2021 , 72, S95-S101	11.6	6
454	Seasonal respiratory viral infections 2021 , 119-131		
453	Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 410-422		4
452	The Effect of Donor Graft Cryopreservation on Allogeneic Hematopoietic Cell Transplantation Outcomes: A Center for International Blood and Marrow Transplant Research Analysis. Implications during the COVID-19 Pandemic. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 507-516		9
451	Prospective Evaluation of Galactomannan and (1->3) β-D-Glucan Assays as Diagnostic Tools for Invasive Fungal Disease in Children, Adolescents, and Young Adults With Acute Myeloid Leukemia Receiving Fungal Prophylaxis. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2021 , 10, 864-871	4.8	4
450	Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis. <i>Cancer Medicine</i> , 2021 , 10, 70-78	4.8	10
449	Hematopoietic Cell Transplantation: Practice Predictions for the Year 2023. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 183.e1-183.e7		2
448	Gut Microbiota Dysbiosis Associated with Persistent Fatigue in Hematopoietic Cell Transplantation Survivors. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 498.e1-498.e8		2
447	COVID-19 and Hematopoietic Cell Transplantation Center-Specific Survival Analysis: Can We Adjust for the Impact of the Pandemic? Recommendations of the COVID-19 Task Force of the 2020 Center for International Blood and Marrow Transplantation Research Center Outcomes Forum. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 522-528		
446	Impact of Changes of the 2020 Consensus Definitions of Invasive Aspergillosis on Clinical Trial Design: Unintended Consequences for Prevention Trials?. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab441	1	0
445	Microbiota phylogenic analysis revealed decreased abundance of <i>Faecalibacterium prausnitzii</i> , an anti-inflammatory commensal bacterium, in patients with chronic graft-versus-host disease. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2021 , 14, 263-265	2.7	

444	Severity of Acute Graft-versus-Host Disease and Associated Healthcare Resource Utilization, Cost, and Outcomes. <i>Transplantation and Cellular Therapy</i> , 2021 ,			1
443	A Prospective Cohort Study Comparing Long-Term Outcomes with and without Palifermin in Patients Receiving Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 837.e1-837.e10			
442	Impact of autologous blood transfusion after bone marrow harvest on unrelated donor's health and outcome: a CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2020 , 55, 2121-2131	4.4		5
441	Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1210-1217	4.7		2
440	Global Metabolomics in Allogeneic Hematopoietic Cell Transplantation Recipients Discordant for Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1803-1810	4.7		3
439	Dietary Intake and Diet Quality of Hematopoietic Stem Cell Transplantation Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1154-1159	4.7		4
438	Safety, feasibility and preliminary efficacy of single agent combretastatin A1 diphosphate (OXi4503) in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2020 , 189, e211-e213	4.5		2
437	Impact of Cryopreservation of Donor Grafts on Outcomes of Allogeneic Hematopoietic Cell Transplant (HCT). <i>Blood</i> , 2020 , 136, 33-34	2.2		
436	Impact of Severity of Acute Graft-Versus-Host Disease on Healthcare Resource Utilization, Cost and Outcomes. <i>Blood</i> , 2020 , 136, 37-38	2.2		
435	Bleeding and thrombosis outcomes in patients with acute leukemia.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e19501-e19501	2.2		1
434	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. <i>Clinical Infectious Diseases</i> , 2020 , 71, 1367-1376	11.6		607
433	Reply to Luppi et al. <i>Clinical Infectious Diseases</i> , 2020 , 71, 3266	11.6		
432	Baseline Gut Microbiota Composition Is Associated with Major Infections Early after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 2001-2010	4.7		6
431	Galectin-3 enhances neutrophil motility and extravasation into the airways during <i>Aspergillus fumigatus</i> infection. <i>PLoS Pathogens</i> , 2020 , 16, e1008741	7.6		18
430	Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2020 ,	4.7		27
429	Clinical predictors of delayed engraftment in autologous hematopoietic cell transplant recipients. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2020 , 13, 23-31	2.7		5
428	Weighty choices: selecting optimal G-CSF doses for stem cell mobilization to optimize yield. <i>Blood Advances</i> , 2020 , 4, 706-716	7.8		7
427	Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. <i>Bone Marrow Transplantation</i> , 2019 , 54, 1354-1360	4.4		15

426 Prevention of Fungal Disease **2019**, 1111-1121

425 Antimicrobial Drug Prophylaxis: Challenges and Controversies **2019**, 1123-1135

424 Effect of Caspofungin vs Fluconazole Prophylaxis on Invasive Fungal Disease Among Children and Young Adults With Acute Myeloid Leukemia: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2019**, 322, 1673-1681 27.4 33

423 Outcomes of autologous blood collection prior to bone marrow harvest for matched unrelated donors.. *Journal of Clinical Oncology*, **2019**, 37, e18535-e18535 2.2

422 Diet Quality of Long-Term Allogeneic and Autologous Stem Cell Transplant (HCT) Survivors. *Blood*, **2019**, 134, 4565-4565 2.2

421 Impact of Renal Dysfunction Measured By Estimated Glomerular Filtration Rate (eGFR) on Outcomes after Allogeneic Hematopoietic Cell Transplantation (HCT). *Blood*, **2019**, 134, 3256-3256 2.2

420 Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy. *Blood Advances*, **2019**, 3, 2836-2844 7.8 24

419 A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients. *Blood Advances*, **2019**, 3, 1837-1847 7.8 8

418 Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. *Blood Advances*, **2019**, 3, 2525-2536 7.8 8

417 Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors. *Haematologica*, **2019**, 104, 1084-1092 6.6 33

416 Tailoring a Survivorship Care Plan: Patient and Provider Preferences for Recipients of Hematopoietic Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 562-569 4.7 12

415 How Clean Is the Linen at My Hospital? The Mucorales on Unclean Linen Discovery Study of Large United States Transplant and Cancer Centers. *Clinical Infectious Diseases*, **2019**, 68, 850-853 11.6 19

414 Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. *Biology of Blood and Marrow Transplantation*, **2019**, 25, 362-368 4.7 24

413 Applying host disease status biomarkers to therapeutic response monitoring in invasive aspergillosis patients. *Medical Mycology*, **2019**, 57, 38-44 3.9 7

412 The Microbiome and Hematopoietic Cell Transplantation: Past, Present, and Future. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1322-1340 4.7 64

411 ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors. *Biology of Blood and Marrow Transplantation*, **2018**, 24, 1119-1124 4.7 15

410 Severity, course, and predictors of sleep disruption following hematopoietic cell transplantation: a secondary data analysis from the BMT CTN 0902 trial. *Bone Marrow Transplantation*, **2018**, 53, 1038-1043 4.4 4

409 Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation. *Journal of Clinical Apheresis*, **2018**, 33, 29-37 3.2 20

408	Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features. <i>Case Reports in Hematology</i> , 2018 , 2018, 9052314	0.7	2
407	PCR-Based Approach Targeting Mucorales-Specific Gene Family for Diagnosis of Mucormycosis. <i>Journal of Clinical Microbiology</i> , 2018 , 56,	9.7	45
406	Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. <i>Lancet Haematology,the</i> , 2018 , 5, e563-e598	14.6	62
405	T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes. <i>Blood</i> , 2018 , 132, 1015-1015	2.2	2
404	Microbiota Phylogenic Analysis Revealed Decreased Abundance of Faecalibacterium Prausnitzii, an Anti-Inflammatory Commensal Bacterium, in Patients with Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2018 , 132, 2119-2119	2.2	1
403	Clinical factors influencing engraftment in patients with non-Hodgkin lymphoma following autologous stem cell transplant.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e19504-e19504	2.2	
402	Platelet count and transfusion dependence as prognostic factors of engraftment in autologous stem cell transplantation.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e20001-e20001	2.2	
401	iCare 1: A prospective clinical trial to predict treatment response based on genomics-informed computational biology in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7024-7024	2.2	
400	Weighty Choices: Selecting Optimal G-CSF Doses for Stem Cell Mobilization to Optimize Yield. <i>Blood</i> , 2018 , 132, 193-193	2.2	
399	Lifestyle Behaviors, Perceived Stress, and Inflammation of Individuals With Chronic Graft-Versus-Host Disease. <i>Cancer Nursing</i> , 2018 , 41, 11-22	2.6	3
398	CD34+ chimerism analysis for minimal residual disease monitoring after allogeneic hematopoietic cell transplantation. <i>Leukemia Research</i> , 2018 , 74, 110-112	2.7	4
397	Vaccinating donors for hematopoietic cell transplantation: A systematic review and future perspectives. <i>Vaccine</i> , 2018 , 36, 6043-6052	4.1	2
396	Infusion of Alloanergized Donor Lymphocytes after CD34-selected Haploidentical Myeloablative Hematopoietic Stem Cell Transplantation. <i>Clinical Cancer Research</i> , 2018 , 24, 4098-4109	12.9	4
395	Viral Infections in Patients with Hematological Malignancies 2018 , 1079-1127		0
394	The microbiome: more than a gut reaction. <i>Blood</i> , 2018 , 131, 2874-2875	2.2	3
393	Expansion of Human Tregs from Cryopreserved Umbilical Cord Blood for GMP-Compliant Autologous Adoptive Cell Transfer Therapy. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017 , 4, 178-191	6.4	36
392	Guarded promise for adenovirus therapy. <i>Blood</i> , 2017 , 129, 1899-1900	2.2	
391	A Prospective Biopsychosocial Investigation Into Head and Neck Cancer Caregiving. <i>Biological Research for Nursing</i> , 2017 , 19, 87-96	2.6	2

390	Paroxysmal Nocturnal Hemoglobinuria in Pregnancy: A Dilemma in Treatment and Thromboprophylaxis. <i>Case Reports in Hematology</i> , 2017 , 2017, 7289126	0.7	3
389	Bosutinib induced pleural effusions: Case report and review of tyrosine kinase inhibitors induced pulmonary toxicity. <i>Respiratory Medicine Case Reports</i> , 2017 , 21, 154-157	1.2	7
388	Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia. <i>Blood Cancer Journal</i> , 2017 , 7, 634	7	14
387	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 870-881	4.7	26
386	Pretransplantation Exercise and Hematopoietic Cell Transplantation Survival: A Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0902). <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 161-164	4.7	8
385	Recent advances in hematopoietic stem cell transplantation. <i>F1000Research</i> , 2017 , 6, 870	3.6	21
384	Community Acquired Respiratory Viral Infections (CARV) in Patients with Acute Leukemia and Hematopoietic Stem Cell Transplant (HSCT) Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, S178	4.7	78
383	Recovery of Unrelated Donors of Peripheral Blood Stem Cells versus Recovery of Unrelated Donors of Bone Marrow: A Prespecified Analysis from the Phase III Blood and Marrow Transplant Clinical Trials Network Protocol 0201. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1108-1116	4.7	18
382	Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells. <i>Cytotherapy</i> , 2016 , 18, 465-80	4.8	17
381	The incidence, mortality and timing of <i>Pneumocystis jiroveci</i> pneumonia after hematopoietic cell transplantation: a CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2016 , 51, 573-80	4.4	48
380	Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis. <i>Bone Marrow Transplantation</i> , 2016 , 51, 277-82	4.4	21
379	Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 359-370	4.7	90
378	Economic Burden of Acute Graft-Versus-Host Disease (GvHD) Following Allogeneic Hematopoietic Cell Transplant (HCT) for Hematologic Malignancies. <i>Blood</i> , 2016 , 128, 1187-1187	2.2	5
377	Icare 1: A Prospective Clinical Trial to Predict Treatment Response Based on Mutanome-Informed Computational Biology in Patients with AML and MDS. <i>Blood</i> , 2016 , 128, 594-594	2.2	1
376	Comparison of Peripheral Blood Stem Cells (PBSC) to Bone Marrow (BM) for T-Replete HLA-Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. <i>Blood</i> , 2016 , 128, 683-683	2.2	3
375	Patient and provider preferences: Treatment summary and survivorship care plans after hematopoietic cell transplant.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 63-63	2.2	3
374	Impact of Novel Agents on Frequency of Second Salvage Autologous Transplantation in Patients with Multiple Myeloma. <i>Blood</i> , 2016 , 128, 5832-5832	2.2	
373	Effect of melphalan 140 mg/m ² vs 200 mg/m ² on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience. <i>Clinical Transplantation</i> , 2016 , 30, 894-900	3.8	10

372	Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016 , 63, e1-e60	11.6	1274
371	Burden, quality of life, and social support in caregivers of patients undergoing radiotherapy for head and neck cancer: A pilot study. <i>Chronic Illness</i> , 2016 , 12, 236-45	1.4	28
370	Impact of early CMV reactivation in cord blood stem cell recipients in the current era. <i>Bone Marrow Transplantation</i> , 2016 , 51, 1113-20	4.4	29
369	Association of mannose-binding lectin levels and invasive fungal disease in hematologic malignancy patients receiving myelosuppressive chemotherapy or allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2016 , 51, 1228-32	4.4	2
368	A new model to predict remission status in AML patients based on day 14 bone marrow biopsy. <i>Leukemia Research</i> , 2016 , 46, 69-73	2.7	11
367	Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2234-40	5.1	10
366	Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. <i>Blood</i> , 2016 , 127, 2427-38	2.2	268
365	A sniff to chase ill humors away. <i>Blood</i> , 2016 , 128, 889-90	2.2	
364	Patient-Reported Outcomes and Socioeconomic Status as Predictors of Clinical Outcomes after Hematopoietic Stem Cell Transplantation: A Study from the Blood and Marrow Transplant Clinical Trials Network 0902 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 2256-2263	4.7	17
363	Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1636-1645	4.7	56
362	Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016 , 63, 433-42	11.6	216
361	Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1915-1925	4.7	82
360	Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902). <i>Cancer</i> , 2016 , 122, 91-8	6.4	46
359	Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1155-66	4.7	87
358	Aspergillus Polymerase Chain Reaction: Systematic Review of Evidence for Clinical Use in Comparison With Antigen Testing. <i>Clinical Infectious Diseases</i> , 2015 , 61, 1293-303	11.6	130
357	Combination antifungal therapy for invasive aspergillosis: a randomized trial. <i>Annals of Internal Medicine</i> , 2015 , 162, 81-9	8	286
356	Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET). <i>Medical Mycology</i> , 2015 , 53, 440-6	3.9	65
355	Center for International Blood and Marrow Transplant Research chronic graft-versus-host disease risk score predicts mortality in an independent validation cohort. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 640-5	4.7	21

354	Secondary solid cancer screening following hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2015 , 50, 1013-23	4.4	100
353	Hepatitis C Virus Infection among Hematopoietic Cell Transplant Donors and Recipients: American Society for Blood and Marrow Transplantation Task Force Recommendations. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1870-82	4.7	43
352	Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1830-8	4.7	9
351	Race and ethnicity influences collection of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from unrelated donors, a Center for International Blood and Marrow Transplant Research analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 165-71	4.7	20
350	Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor. <i>Bone Marrow Transplantation</i> , 2015 , 50, 197-203	4.4	27
349	Impact of Chronic Graft-versus-Host Disease on Late Relapse and Survival on 7,489 Patients after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Leukemia. <i>Clinical Cancer Research</i> , 2015 , 21, 2020-8	12.9	69
348	Vitamin D effect on umbilical cord blood characteristics: a comparison between African Americans and Caucasians. <i>Transfusion</i> , 2015 , 55, 1766-71	2.9	5
347	Improved Detection of Invasive Pulmonary Aspergillosis Arising during Leukemia Treatment Using a Panel of Host Response Proteins and Fungal Antigens. <i>PLoS ONE</i> , 2015 , 10, e0143165	3.7	19
346	Valganciclovir for the prevention of complications of late cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a randomized trial. <i>Annals of Internal Medicine</i> , 2015 , 162, 1-10	8	97
345	Relationships among symptoms, psychosocial factors, and health-related quality of life in hematopoietic stem cell transplant survivors. <i>Supportive Care in Cancer</i> , 2015 , 23, 797-807	3.9	36
344	Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells. <i>Blood</i> , 2015 , 125, 3778-88	2.2	23
343	Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndrome. <i>Leukemia Research Reports</i> , 2015 , 4, 24-7	0.6	14
342	Comparison of Characteristics and Outcomes of Trial Participants and Nonparticipants: Example of Blood and Marrow Transplant Clinical Trials Network 0201 Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 1815-22	4.7	8
341	Effect of cord blood processing on transplantation outcomes after single myeloablative umbilical cord blood transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, 688-95	4.7	15
340	More Infections with Transplantation of Bone Marrow, Versus Peripheral-Blood Stem Cells, from Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2015 , 21, S49-S50	4.7	3
339	The Vascular Disrupting Agent OXi4503 in Relapsed and Refractory AML and MDS. <i>Blood</i> , 2015 , 126, 4936-4936	2.2	3
338	Effect of Melphalan 140 Mg/m ² Versus 200 Mg/m ² on Toxicities and Outcomes in Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Transplantation. <i>Blood</i> , 2015 , 126, 1988-1988 ²		
337	A New Model to Predict Remission Status in Acute Myeloid Leukemia (AML) Patients Based on Day 14 Bone Marrow (D14 BM) Biopsy. <i>Blood</i> , 2015 , 126, 3852-3852	2.2	

336	Minimal Residual Disease (MRD) By Either Flow Cytometry or Cytogenetics Prior to an Allogeneic Hematopoietic Cell Transplant (allo-HCT) Predicts Poor Acute Myeloid Leukemia (AML) Outcomes. <i>Blood</i> , 2015 , 126, 3221-3221	2.2	
335	Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 658-64	4.7	61
334	Long-term stability at -20 °C of <i>Aspergillus galactomannan</i> in serum and bronchoalveolar lavage specimens. <i>Journal of Clinical Microbiology</i> , 2014 , 52, 2108-11	9.7	13
333	Reduction in false-positive <i>Aspergillus</i> serum galactomannan enzyme immunoassay results associated with use of piperacillin-tazobactam in the United States. <i>Journal of Clinical Microbiology</i> , 2014 , 52, 2199-201	9.7	46
332	Elevated incidence of chronic myeloid leukaemia in immunosuppressed solid organ transplant recipients. <i>British Journal of Haematology</i> , 2014 , 166, 619-21	4.5	5
331	Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients. <i>Clinical Infectious Diseases</i> , 2014 , 59 Suppl 5, S352-5	11.6	40
330	Reply to "Insufficient demonstration of long-term stability of <i>Aspergillus galactomannan</i> ". <i>Journal of Clinical Microbiology</i> , 2014 , 52, 4119	9.7	3
329	Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1777-84	4.7	40
328	Peripheral blood progenitor cell mobilization for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1262-73	4.7	130
327	Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 600-16	4.7	49
326	Health-related quality of life of bone marrow versus peripheral blood stem cell donors: a prespecified subgroup analysis from a phase III RCT-BMTCTN protocol 0201. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 118-27	4.7	25
325	Exercise and stress management training prior to hematopoietic cell transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1530-6	4.7	60
324	Clinical guide to fertility preservation in hematopoietic cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2014 , 49, 477-84	4.4	75
323	Tandem Autologous Stem Cell Transplantation for Multiple Myeloma Patients Based on Response to Their First Transplant-A Prospective Phase II Study. <i>Clinical Medicine Insights: Oncology</i> , 2014 , 8, 101-5 ^{1.8}		5
322	Aztreonam for febrile neutropenia in patients with beta-lactam allergy. <i>Transplant Infectious Disease</i> , 2014 , 16, 145-52	2.7	5
321	Patient-Reported Quality of Life Is an Independent Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation: A Secondary Analysis from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902. <i>Blood</i> , 2014 , 124, 206-206	2.2	6
320	Severe Diffuse Alveolar Hemorrhage Associated with Bortezomib Administration in Patients with Multiple Myeloma. <i>Blood</i> , 2014 , 124, 5761-5761	2.2	3
319	Do Hematopoietic Cell Transplant Patients Treated on a Clinical Trial Do Better? Comparison of Characteristics and Outcomes of Patients Enrolled Versus Not Enrolled on Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0201 Trial. <i>Blood</i> , 2014 , 124, 209-209	2.2	

318	Advances in the management of viral infections. <i>Cancer Treatment and Research</i> , 2014 , 161, 157-80	3.5	
317	Physician perceptions and practice patterns regarding fertility preservation in hematopoietic cell transplant recipients. <i>Bone Marrow Transplantation</i> , 2013 , 48, 1091-7	4.4	4 ⁸
316	Continuous infusion cyclophosphamide and low-dose total body irradiation is a safe and effective conditioning regimen for autologous transplant in multiple myeloma. <i>Transplantation Proceedings</i> , 2013 , 45, 3361-5	1.1	8
315	Extramedullary disease in plasma cell myeloma: the iceberg phenomenon. <i>Bone Marrow Transplantation</i> , 2013 , 48, 10-8	4.4	33
314	Randomized, Double Blind, Placebo-Controlled Trial of a TNF Inhibitor (ETANERCEPT) for the Treatment of Idiopathic Pneumonia Syndrome (IPS) After Allogeneic Stem Cell Transplant (SCT). A Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Study. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, S169	4.7	3
313	Development and evaluation of a calibrator material for nucleic acid-based assays for diagnosing aspergillosis. <i>Journal of Clinical Microbiology</i> , 2013 , 51, 2403-5	9.7	21
312	Viral Infections in Patients with Hematological Malignancies 2013 , 1193-1239		
311	Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with Type 1 diabetes. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1126-9	4.7	41
310	Umbilical cord blood graft enhancement strategies: has the time come to move these into the clinic?. <i>Bone Marrow Transplantation</i> , 2013 , 48, 884-9	4.4	33
309	Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. <i>American Journal of Health-System Pharmacy</i> , 2013 , 70, 1518-27	2.2	10
308	Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donation: results of a prospective trial from the National Marrow Donor Program. <i>Blood</i> , 2013 , 121, 197-206	2.2	106
307	Diagnostic strategies for invasive fungal infections in patients with hematologic malignancies and hematopoietic stem cell transplant recipients. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013 , 11, 941-9	7.3	8
306	A Phase I Study Of The Vascular Disrupting Combretastatin, OXi4503, In Patients With Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2013 , 122, 1463-1463	2.2	9
305	Exercise and Stress Management Training For Patients Undergoing Autologous Or Allogeneic Hematopoietic Cell Transplantation. Results From Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902. <i>Blood</i> , 2013 , 122, 699-699	2.2	1
304	Vitamin D Effect On Umbilical Cord Blood Characteristics: A Comparison Between African Americans and Caucasians. <i>Blood</i> , 2013 , 122, 693-693	2.2	
303	Effect Of Cumulative Adverse Clinical Risk Factors On Patients With Multiple Myeloma Undergoing First G-CSF Apheresis. <i>Blood</i> , 2013 , 122, 4520-4520	2.2	
302	Influence Of Race and Ethnicity On The Collection Of G-CSF Mobilized Peripheral Blood Stem Cells From Unrelated Donors, a Center For International Blood and Marrow Transplant Research Analysis. <i>Blood</i> , 2013 , 122, 3273-3273	2.2	
301	Clinical and Laboratory Factors Influencing The Probability Of Complete Remission In AML Patients With Positive Day 14 Bone Marrows. <i>Blood</i> , 2013 , 122, 1412-1412	2.2	

300	Characteristics of thawed autologous umbilical cord blood. <i>Transfusion</i> , 2012 , 52, 2234-42	2.9	15
299	Quality of life, social challenges, and psychosocial support for long-term survivors after allogeneic hematopoietic stem-cell transplantation. <i>Seminars in Hematology</i> , 2012 , 49, 104-9	4	35
298	Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3194-201	2.2	124
297	Serum IgG responses against Aspergillus proteins before hematopoietic stem cell transplantation or chemotherapy identify patients who develop invasive aspergillosis. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1927-34	4.7	13
296	Phase II trial of parathyroid hormone after double umbilical cord blood transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1851-8	4.7	24
295	Relationship of race/ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 903-12	4.7	38
294	Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 348-71	4.7	261
293	Armed killers face off against cytomegalovirus. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 977-8	4.7	2
292	First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 1150-63	4.7	399
291	Have novel serum markers supplanted tissue diagnosis for invasive fungal infections in acute leukemia and transplantation?. <i>Best Practice and Research in Clinical Haematology</i> , 2012 , 25, 487-91	4.2	11
290	African American adult apheresis donors respond to granulocyte-colony-stimulating factor with neutrophil and progenitor cell yields comparable to those of Caucasian and Hispanic donors. <i>Transfusion</i> , 2012 , 52, 166-72	2.9	9
289	Use of antibacterial prophylaxis in patients with chemotherapy-induced neutropenia. <i>Current Opinion in Hematology</i> , 2012 , 19, 21-6	3.3	20
288	Peripheral-blood stem cells versus bone marrow from unrelated donors. <i>New England Journal of Medicine</i> , 2012 , 367, 1487-96	59.2	620
287	How I manage pulmonary nodular lesions and nodular infiltrates in patients with hematologic malignancies or undergoing hematopoietic cell transplantation. <i>Blood</i> , 2012 , 120, 1791-800	2.2	46
286	Diagnostic methods for invasive fungal diseases in patients with hematologic malignancies. <i>Expert Review of Hematology</i> , 2012 , 5, 661-9	2.8	13
285	Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2012 , 5, 1-30	2.7	61
284	Tacrolimus/Sirolimus Vs. Tacrolimus/Methotrexate for Graft-Vs.-Host Disease Prophylaxis After HLA-Matched, Related Donor Hematopoietic Stem Cell Transplantation: Results of Blood and Marrow Transplant Clinical Trials Network Trial 0402. <i>Blood</i> , 2012 , 120, 739-739	2.2	14
283	Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2012 , 34, 109-33		37

282	Response Post-First Autologous Stem Cell Transplantation for Multiple Myeloma May Identify Patients Who Will Benefit From Tandem Transplants: A Single Center Prospective Phase II Study- an Update. <i>Blood</i> , 2012 , 120, 2023-2023	2.2	
281	Continuous Infusion Cyclophosphamide and Low Dose Total Body Irradiation (CICy/IdTBI) As a Conditioning Regimen for Tandem Autologous Transplant in Multiple Myeloma. <i>Blood</i> , 2012 , 120, 4524-4524	2.2	22
280	Peripheral Blood CD34+ Specific Donor Chimerism Analysis As an Early Indicator of Disease Relapse After Allogeneic Hematopoietic Stem Cell Transplant in Patients with Myelodysplastic Syndromes and Acute Myelogenous Leukemia.. <i>Blood</i> , 2012 , 120, 3074-3074	2.2	
279	A Phase I Study of the Vascular Disrupting Combretastatin, OXi4503, in Patients with Relapsed and Refractory Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2012 , 120, 4335-4335	2.2	23
278	Higher Than Expected Incidence of Chronic Myeloid Leukemia in Solid Organ Transplant Recipients.. <i>Blood</i> , 2012 , 120, 2799-2799	2.2	
277	Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. <i>Hematology/Oncology Clinics of North America</i> , 2011 , 25, 101-16	3.1	42
276	Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 157-66	4.7	72
275	Generic immunosuppressants in hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 285-90	4.7	11
274	Galactomannan testing in bronchoalveolar lavage fluid facilitates the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies and stem cell transplant recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1043-50	4.7	64
273	Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1375-82	4.7	162
272	Malignancies after hematopoietic cell transplantation for primary immune deficiencies: a report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2011 , 17, 1783-9	4.7	25
271	Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. <i>Blood</i> , 2011 , 117, 6714-20	2.2	105
270	Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. <i>Emerging Infectious Diseases</i> , 2011 , 17, 1855-64	10.2	209
269	Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. <i>Blood</i> , 2011 , 117, 316-22	2.2	150
268	Pandemic influenza: was the concern warranted?. <i>Blood</i> , 2011 , 117, 5012-3	2.2	
267	Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. <i>Blood</i> , 2011 , 118, 282-8	2.2	476
266	Risk factors associated with increased nonrelapse mortality and with poor overall survival in children with chronic graft-versus-host disease. <i>Blood</i> , 2011 , 118, 4472-9	2.2	41
265	Autologous umbilical cord blood transfusion in young children with type 1 diabetes fails to preserve C-peptide. <i>Diabetes Care</i> , 2011 , 34, 2567-9	14.6	55

264	Assessing responses to treatment of opportunistic mycoses and salvage strategies. <i>Current Infectious Disease Reports</i> , 2011 , 13, 492-503	3.9	3
263	Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. <i>Clinical Infectious Diseases</i> , 2011 , 52, e56-93	11.6	1797
262	Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2230-9	2.2	408
261	Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2011 , 52, 427-31	11.6	516
260	Comparison of lasting life changes after cancer and BMT: perspectives of long-term survivors and spouses. <i>Psycho-Oncology</i> , 2011 , 20, 926-34	3.9	18
259	Increased Incidence of Chronic Graft-Versus-Host Disease (GVHD) and No Survival Advantage with Filgrastim-Mobilized Peripheral Blood Stem Cells (PBSC) Compared to Bone Marrow (BM) Transplants From Unrelated Donors: Results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0201, a Phase III, Prospective, Randomized Trial. <i>Blood</i> , 2011 , 118, 141	2.2	14
258	Controversies in Empiric Therapy of Febrile Neutropenia 2011 , 105-111		
257	Antibacterial, Antifungal, and Antiviral Prophylaxis in High-Risk Cancer and Stem Cell Transplant Population 2011 , 521-531		
256	Reinduction Chemotherapy for AML: Comparison Between CECA, High Dose Cytarabine and CLAG-M. <i>Blood</i> , 2011 , 118, 4301-4301	2.2	
255	Negative Correlation Between the Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) and Total Hospital Stay in Patients Who Underwent Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT). <i>Blood</i> , 2011 , 118, 4462-4462	2.2	
254	CECA Results in Improved Response Rates and Ability to Proceed to Stem Cell Transplantation in Adult Refractory or Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2011 , 118, 4299-4299	2.2	
253	Reduced-intensity conditioning using fludarabine with either antithymocyte globulin and BU, or low-dose TBI allowing allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2010 , 45, 31-7	4.4	2
252	Combination of IFN- γ /GM-CSF as a Maintenance Therapy for Multiple Myeloma Patients After Autologous Stem Cell Transplantation (ASCT): A Prospective Phase II Study. <i>Clinical Medicine Insights: Oncology</i> , 2010 , 4, 117-25	1.8	5
251	Factors associated with mortality in transplant patients with invasive aspergillosis. <i>Clinical Infectious Diseases</i> , 2010 , 50, 1559-67	11.6	223
250	Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. <i>Clinical Infectious Diseases</i> , 2010 , 50, 1091-100	11.6	991
249	Serological profiling of a <i>Candida albicans</i> protein microarray reveals permanent host-pathogen interplay and stage-specific responses during candidemia. <i>PLoS Pathogens</i> , 2010 , 6, e1000827	7.6	58
248	Hematopoietic stem cell transplantation: an overview of infection risks and epidemiology. <i>Infectious Disease Clinics of North America</i> , 2010 , 24, 257-72	6.5	113
247	<i>Aspergillus</i> DNA contamination in blood collection tubes. <i>Diagnostic Microbiology and Infectious Disease</i> , 2010 , 67, 392-4	2.9	46

246	Antifungal management. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 441-2	4.7	3
245	The National Marrow Donor Program's symposium on patient advocacy in cellular transplantation therapy: addressing barriers to hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 147-56	4.7	13
244	The preventive health behaviors of long-term survivors of cancer and hematopoietic stem cell transplantation compared with matched controls. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 207-14	4.7	58
243	Spiritual absence and 1-year mortality after hematopoietic stem cell transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1171-9	4.7	40
242	Factors associated with self-reported physical and mental health after hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 1682-92	4.7	34
241	Drug-induced nephrotoxicity caused by amphotericin B lipid complex and liposomal amphotericin B: a review and meta-analysis. <i>Medicine (United States)</i> , 2010 , 89, 236-244	1.8	66
240	Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2010 , 116, 5111-8	2.2	358
239	Relationship of Race/Ethnicity and Survival After Single Umbilical Cord Blood Transplantation. <i>Blood</i> , 2010 , 116, 224-224	2.2	1
238	Amphotericin B (AMB) 2010 , 1693-1727		
237	Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Scores Correlates with Increased Readmissions and Days In Hospital In Patients Undergoing Myeloablative Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2010 , 116, 4748-4748	2.2	
236	Chronic Graft-Versus-Host Disease Risk Score: A CIBMTR Analysis. <i>Blood</i> , 2010 , 116, 898-898	2.2	
235	Risk Factors for Major Transplant Related Outcomes In Pediatric Patients with Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2010 , 116, 211-211	2.2	
234	Health-Related Quality-of-Life Among Adult Matched Unrelated Stem Cell Donors: A Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Randomized Trial of Marrow Versus PBSC Donation. <i>Blood</i> , 2010 , 116, 366-366	2.2	1
233	Hypomethylating agent induction therapy followed by hematopoietic cell transplantation is feasible in patients with myelodysplastic syndromes. <i>Clinical Advances in Hematology and Oncology</i> , 2010 , 8, 40-6	0.6	23
232	Current approaches in antifungal prophylaxis in high risk hematologic malignancy and hematopoietic stem cell transplant patients. <i>Mycopathologia</i> , 2009 , 168, 299-311	2.9	21
231	Fungal infection prevention after hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2009 , 44, 483-7	4.4	43
230	<i>Strongyloides stercoralis</i> hyperinfection in hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , 2009 , 11, 143-8	2.7	42
229	Strategies for minimizing complications of neutropenia: prophylactic myeloid growth factors or antibiotics. <i>Critical Reviews in Oncology/Hematology</i> , 2009 , 72, 144-54	7	38

228	Autologous umbilical cord blood transfusion in very young children with type 1 diabetes. <i>Diabetes Care</i> , 2009 , 32, 2041-6	14.6	74
227	Methodology for updating published evidence-based reviews evaluating the role of blood and marrow transplantation in the treatment of selected diseases: a policy statement by the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 761-2	4.7	8
226	Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 1143-238	4.7	1223
225	Solid cancers after allogeneic hematopoietic cell transplantation. <i>Blood</i> , 2009 , 113, 1175-83	2.2	358
224	The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. <i>Blood</i> , 2009 , 113, 3110-8	2.2	136
223	Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. <i>Blood</i> , 2009 , 113, 5074-82	2.2	120
222	Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. <i>Blood</i> , 2009 , 114, 511-7	2.2	188
221	Stem Cell Transplantation 2009 , 211-231		
220	Clinical Manifestations of Invasive Pulmonary Aspergillosis 2009 , 381-389		
219	Long-Term Survival and Late Deaths in 2-Year Survivors of Myeloablative Allogeneic Hematopoietic-Cell Transplantation for Hematologic Disorders.. <i>Blood</i> , 2009 , 114, 520-520	2.2	
218	Bone marrow sinusoidal endothelial cells undergo nonapoptotic cell death and are replaced by proliferating sinusoidal cells in situ to maintain the vascular niche following lethal irradiation. <i>Experimental Hematology</i> , 2008 , 36, 1143-1156	3.1	50
217	Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. <i>Clinical Infectious Diseases</i> , 2008 , 47, 1813-24	11.6	3744
216	Flow cytometric minimal residual disease monitoring in patients with multiple myeloma undergoing autologous stem cell transplantation: a retrospective study. <i>Leukemia and Lymphoma</i> , 2008 , 49, 306-14	1.9	22
215	Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2008 , 46, 327-60	11.6	2097
214	Tratamiento de la Aspergilosis: Guías para la práctica clínica de la Sociedad de Enfermedades Infecciosas de los Estados Unidos de América (IDSA). <i>Clinical Infectious Diseases</i> , 2008 , 46, T1-T36	11.6	2
213	Performance characteristics of the platelia Aspergillus enzyme immunoassay for detection of Aspergillus galactomannan antigen in bronchoalveolar lavage fluid. <i>Vaccine Journal</i> , 2008 , 15, 1760-3		82
212	Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. <i>Clinical Infectious Diseases</i> , 2008 , 47, 674-83	11.6	308
211	Immunoglobulin G responses to a panel of Candida albicans antigens as accurate and early markers for the presence of systemic candidiasis. <i>Journal of Clinical Microbiology</i> , 2008 , 46, 1647-54	9.7	46

210	Learning from our failures: the antifungal treatment conundrum. <i>Clinical Infectious Diseases</i> , 2008 , 46, 1434-5	11.6	9
209	Transplanted human cord blood cells generate amylase-producing pancreatic acinar cells in engrafted mice. <i>Pancreas</i> , 2008 , 36, e30-5	2.6	7
208	Influenza: preparedness for an inevitable "Emergency" for oncology and BMT units. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2008 , 6, 215-22	7.3	10
207	Combination antifungal therapy: from bench to bedside. <i>Current Infectious Disease Reports</i> , 2008 , 10, 466-72	3.9	13
206	Combination antifungal therapy: From bench to bedside. <i>Current Fungal Infection Reports</i> , 2008 , 2, 43-48	1.4	6
205	Changes in causes of death over time after treatment for invasive aspergillosis. <i>Cancer</i> , 2008 , 112, 2309-14	6.4	67
204	BMT CTN 0302: A Phase II Randomized Trial Evaluating Etanercept, Mycophenolate Mofetil (MMF), Denileukin Diftitox, and Pentostatin in Combination with Corticosteroids in 180 Patients (pts) with Newly Diagnosed Acute Graft Vs. Host Disease (aGVHD). <i>Blood</i> , 2008 , 112, 55-55	2.2	3
203	Effect of the Absolute Lymphocyte Count on Induction Chemotherapy Outcomes in Adult Patients with Acute Leukemia. <i>Blood</i> , 2008 , 112, 4853-4853	2.2	
202	New approaches to invasive fungal infections in acute leukemia and hematopoietic stem cell transplant patients. <i>Best Practice and Research in Clinical Haematology</i> , 2007 , 20, 99-107	4.2	17
201	Unrelated cord blood transplantation in children with sickle cell disease: review of four-center experience. <i>Pediatric Transplantation</i> , 2007 , 11, 641-4	1.8	64
200	Resource use and cost of treatment with voriconazole or conventional amphotericin B for invasive aspergillosis. <i>Transplant Infectious Disease</i> , 2007 , 9, 182-8	2.7	24
199	Sites and kinetics of donor thrombopoiesis following transplantation of whole bone marrow and progenitor subsets. <i>Experimental Hematology</i> , 2007 , 35, 1567-79	3.1	2
198	The role of the donor in the repair of the marrow vascular niche following hematopoietic stem cell transplant. <i>Stem Cells</i> , 2007 , 25, 2945-55	5.8	51
197	Pathogenesis of <i>Aspergillus fumigatus</i> and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. <i>Journal of Infectious Diseases</i> , 2007 , 195, 455-66	7	110
196	Use of bronchoalveolar lavage to detect galactomannan for diagnosis of pulmonary aspergillosis among nonimmunocompromised hosts. <i>Journal of Clinical Microbiology</i> , 2007 , 45, 2787-92	9.7	77
195	Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. <i>Clinical Infectious Diseases</i> , 2007 , 44, 402-9	11.6	150
194	Pharmacoeconomic analysis of caspofungin versus liposomal amphotericin B as empirical antifungal therapy for neutropenic fever. <i>American Journal of Health-System Pharmacy</i> , 2007 , 64, 637-43	2.2	28
193	Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. <i>Journal of Clinical Microbiology</i> , 2007 , 45, 1759-65	9.7	165

192	Late effects of cancer and hematopoietic stem-cell transplantation on spouses or partners compared with survivors and survivor-matched controls. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1403-11	2.2	145
191	Reply to Verweij et al. <i>Clinical Infectious Diseases</i> , 2007 , 44, 1667-1668	11.6	3
190	Spatial distribution of blood vessels and CD34+ hematopoietic stem and progenitor cells within the marrow cavities of human cancellous bone. <i>Journal of Nuclear Medicine</i> , 2007 , 48, 645-54	8.9	30
189	Facing the Next Pandemic: Ready or Not. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 107-109	4.7	8
188	Radiation Emergencies: Evaluation, Management, and Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 103-106	4.7	5
187	Umbilical cord blood produces small megakaryocytes after transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 145-50	4.7	21
186	Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 1461-8	4.7	154
185	Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. <i>Clinical Infectious Diseases</i> , 2007 , 44, 373-9	11.6	452
184	Results of a Randomized, Double-Blind Trial of Fluconazole (FLU) vs. Voriconazole (VORI) for the Prevention of Invasive Fungal Infections (IFI) in 600 Allogeneic Blood and Marrow Transplant (BMT) Patients.. <i>Blood</i> , 2007 , 110, 163-163	2.2	41
183	Graft-Versus-Leukemia Effect Is Equivalent in Recipients of Matched Sibling and Matched Unrelated Donor Conventional Hematopoietic Cell Transplant.. <i>Blood</i> , 2007 , 110, 3049-3049	2.2	
182	Bone Marrow Sinusoidal Endothelium Undergoes DNA Damage and Repair Following Lethal Irradiation.. <i>Blood</i> , 2007 , 110, 4866-4866	2.2	
181	Wilm's Tumor 1 Gene Expression Is a Useful Marker for Minimal Residual Disease in Acute Myeloid Leukemia.. <i>Blood</i> , 2007 , 110, 4240-4240	2.2	
180	Posaconazole as salvage therapy for zygomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2006 , 50, 126-33	5.9	469
179	Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt. <i>Clinical Infectious Diseases</i> , 2006 , 43, 1031-9	11.6	2
178	Invasive Fungal Pathogens: Current Epidemiological Trends. <i>Clinical Infectious Diseases</i> , 2006 , 43, S3-S14	11.6	300
177	Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 325-34	4.7	201
176	Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 325-34	4.7	62
175	Preparing for the unthinkable: emergency preparedness for the hematopoietic cell transplant program. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 1229-38	4.7	7

174	Is combination antifungal therapy for invasive aspergillosis a necessity in hematopoietic stem-cell transplant recipients?. <i>Current Opinion in Infectious Diseases</i> , 2006 , 19, 371-9	5.4	6
173	Factors associated with parameters of engraftment potential of umbilical cord blood. <i>Transfusion</i> , 2006 , 46, 1803-12	2.9	45
172	New strategies of antifungal therapy in hematopoietic stem cell transplant recipients and patients with hematological malignancies. <i>Blood Reviews</i> , 2006 , 20, 267-87	11.1	21
171	Flow Cytometric Disease Monitoring in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation: A Retrospective Study.. <i>Blood</i> , 2006 , 108, 5014-5014	2.2	
170	Long-term health-related quality of life, growth, and spiritual well-being after hematopoietic stem-cell transplantation. <i>Journal of Clinical Oncology</i> , 2005 , 23, 599-608	2.2	257
169	Tandem autografts for multiple myeloma patients using two different conditioning regimens: An interim analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 65-66	4.7	69
168	An assay for human hematopoietic stem cells based on transplantation into nonobese diabetic recombination activating gene-null perforin-null mice. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 487-94	4.7	6
167	Increased levels of tumor necrosis factor alpha are associated with an increased risk of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 698-705	4.7	12
166	Interleukin 12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 1014-21	4.7	39
165	National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 945-56	4.7	2749
164	Caspofungin versus amphotericin B for candidemia: a pharmacoeconomic analysis. <i>Clinical Therapeutics</i> , 2005 , 27, 960-9	3.5	22
163	Developmental differences in megakaryocyte maturation are determined by the microenvironment. <i>Stem Cells</i> , 2005 , 23, 1400-8	5.8	36
162	The changing face of invasive fungal infections in hematopoietic cell transplant recipients. <i>Current Opinion in Oncology</i> , 2005 , 17, 89-92	4.2	42
161	Study of renal safety in amphotericin B lipid complex-treated patients. <i>Clinical Infectious Diseases</i> , 2005 , 40 Suppl 6, S414-21	11.6	54
160	Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. <i>Clinical Infectious Diseases</i> , 2005 , 41, 1448-52	11.6	94
159	Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. <i>Clinical Infectious Diseases</i> , 2005 , 41, 654-9	11.6	560
158	Unrelated Cord Blood Transplantation (UCBT) in Children with Sickle Cell Disease (SCD): US Centers Experience.. <i>Blood</i> , 2005 , 106, 2044-2044	2.2	3
157	Donor-Derived Hematopoietic Stem Cells Repair the Bone Marrow Sinusoids Following Bone Marrow Transplant.. <i>Blood</i> , 2005 , 106, 1714-1714	2.2	

156	Treatment of zygomycosis with posaconazole in a patient with acute myeloid leukemia. <i>Clinical Advances in Hematology and Oncology</i> , 2005 , 3, 773-7	0.6	11
155	Reply to Powers. <i>Clinical Infectious Diseases</i> , 2004 , 39, 1739-1739	11.6	1
154	The design of clinical trials that evaluate antifungal prophylaxis and combination therapy: introduction and overview. <i>Clinical Infectious Diseases</i> , 2004 , 39 Suppl 4, S165-9	11.6	7
153	Empirical antifungal therapy in treating febrile neutropenic patients. <i>Clinical Infectious Diseases</i> , 2004 , 39 Suppl 1, S38-43	11.6	56
152	Supportive care. <i>Hematology American Society of Hematology Education Program</i> , 2004 , 2004, 372-89	3.1	10
151	Design issues in a prospective randomized double-blinded trial of prophylaxis with fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation. <i>Clinical Infectious Diseases</i> , 2004 , 39 Suppl 4, S176-80	11.6	19
150	Granulocytic sarcoma (chloroma) of the breast: a diagnostic dilemma and review of the literature. <i>Breast Journal</i> , 2004 , 10, 48-53	1.2	29
149	Transplantation of unrelated placental blood cells in children with high-risk sickle cell disease. <i>Bone Marrow Transplantation</i> , 2004 , 34, 405-11	4.4	35
148	A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. <i>Leukemia Research</i> , 2004 , 28, 559-65	2.7	55
147	Thriving after hematopoietic stem cell transplant: a focus on positive changes in quality of life. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2004 , 4, 111-23	2.2	7
146	A new era of antifungal therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2004 , 10, 73-90	4.7	85
145	The gift of life comes with a price: the impact of hematopoietic cell transplant on the long-term quality of life of survivors and their spouses. <i>Biology of Blood and Marrow Transplantation</i> , 2004 , 10, 7-8	4.7	4
144	Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2004 , 10, 614-23	4.7	29
143	Clinical consequences of oral mucositis. <i>Seminars in Oncology Nursing</i> , 2004 , 20, 16-21	3.7	39
142	Bone marrow transdifferentiation in brain after transplantation: a retrospective study. <i>Lancet, The</i> , 2004 , 363, 1432-7	4.0	268
141	Physicians' attitudes about quality-of-life issues in hematopoietic stem cell transplantation. <i>Blood</i> , 2004 , 104, 2194-200	2.2	75
140	Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease. <i>Blood</i> , 2004 , 103, 4330-5	2.2	96
139	High Levels of Interleukin-12 Are Associated with Reduced Incidence of Relapse and Death without Increasing Acute Graft-Versus-Host Disease (AGVHD) after Allogeneic Stem Cell Transplantation (SCT).. <i>Blood</i> , 2004 , 104, 295-295	2.2	

138	NOD-Rag1nullPrf1null Mice Support Long-Term Engraftment of Human Hematopoietic Stem Cells.. <i>Blood</i> , 2004 , 104, 1184-1184	2.2	
137	Incorporation of Bone Marrow Derived Cells in Colonic Adenoma.. <i>Blood</i> , 2004 , 104, 674-674	2.2	
136	Hospital Resource Utilization in Acute Invasive Aspergillosis (AIA) Patients (Pts) Treated with Voriconazole (VOR) or Amphotericin B (CAB).. <i>Blood</i> , 2004 , 104, 88-88	2.2	
135	Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy. <i>Cancer</i> , 2003 , 98, 406-12	6.4	47
134	Access to stem cell transplantation: do women fare as well as men?. <i>American Journal of Hematology</i> , 2003 , 72, 99-102	7.1	14
133	Busulfan, cyclophosphamide, and etoposide as conditioning for autologous stem cell transplantation in multiple myeloma. <i>American Journal of Hematology</i> , 2003 , 73, 169-75	7.1	19
132	Autologous stem cell transplantation in multiple myeloma patients \geq 60 years of age. <i>Bone Marrow Transplantation</i> , 2003 , 32, 1135-43	4.4	63
131	Human cord blood long-term engrafting cells are CD34+ CD38-. <i>Leukemia</i> , 2003 , 17, 960-4	10.7	46
130	Transplanted human cord blood cells give rise to hepatocytes in engrafted mice. <i>Annals of the New York Academy of Sciences</i> , 2003 , 996, 174-85	6.5	116
129	Intravenous busulfan in pretransplant chemotherapy: bioavailability and patient benefit. <i>Biology of Blood and Marrow Transplantation</i> , 2003 , 9, 722-4	4.7	16
128	The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. <i>Biology of Blood and Marrow Transplantation</i> , 2003 , 9, 4-37	4.7	76
127	Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. <i>Biology of Blood and Marrow Transplantation</i> , 2003 , 9, 543-58	4.7	348
126	Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2003 , 44, 815-20	1.9	80
125	A phase III, randomized, double-blind, placebo-controlled, multinational trial of isegagan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial). <i>Leukemia and Lymphoma</i> , 2003 , 44, 1165-72	1.9	51
124	An assay for long-term engrafting human hematopoietic cells based on newborn NOD/SCID/beta2-microglobulin(null) mice. <i>Experimental Hematology</i> , 2002 , 30, 488-94	3.1	45
123	Human stem-progenitor cells from neonatal cord blood have greater hematopoietic expansion capacity than those from mobilized adult blood. <i>Experimental Hematology</i> , 2002 , 30, 816-23	3.1	72
122	Racial and ethnic composition of volunteer cord blood donors: comparison with volunteer unrelated marrow donors. <i>Transfusion</i> , 2002 , 42, 1279-84	2.9	40
121	Human CD34+ hematopoietic stem/progenitor cells express high levels of FLIP and are resistant to Fas-mediated apoptosis. <i>Stem Cells</i> , 2002 , 20, 174-82	5.8	56

120	Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels. <i>Leukemia and Lymphoma</i> , 2002 , 43, 989-99	1.9	11
119	Increased risk of lethal graft-versus-host disease-like syndrome after transplantation into NOD/SCID mice of human mobilized peripheral blood stem cells, as compared to bone marrow or cord blood. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002 , 11, 277-92		21
118	Factors associated with increased hospital costs in patients treated with lipid-based amphotericin B for empirical therapy. <i>Journal of Medical Economics</i> , 2002 , 5, 109-118	2.4	9
117	Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. <i>New England Journal of Medicine</i> , 2002 , 346, 225-34	59.2	802
116	Lipid formulations of amphotericins: are you a lump or a splitter?. <i>Clinical Infectious Diseases</i> , 2002 , 35, 891-5	11.6	51
115	A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. <i>Clinical Infectious Diseases</i> , 2002 , 35, 359-66	11.6	272
114	Antifungal chemoprophylaxis after blood and marrow transplantation. <i>Clinical Infectious Diseases</i> , 2002 , 34, 1386-90	11.6	26
113	Stem cell transplantation: supportive care and long-term complications. <i>Hematology American Society of Hematology Education Program</i> , 2002 , 2002, 422-44	3.1	58
112	Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. <i>Bone Marrow Transplantation</i> , 2002 , 29, 15-9	4.4	149
111	Prophylaxis, empirical therapy, or pre-emptive therapy of fungal infections in immunocompromised patients: which is better for whom?. <i>Current Opinion in Infectious Diseases</i> , 2002 , 15, 369-75	5.4	16
110	Mismanaging the gift of life: noncompliance in the context of adult stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2002 , 29, 875-80	4.4	14
109	GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation. <i>Cytotherapy</i> , 2002 , 4, 531-8	4.8	5
108	Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. <i>New England Journal of Medicine</i> , 2002 , 347, 408-15	59.2	2596
107	A prospective randomized trial of prophylactic platelet transfusion and bleeding incidence in hematopoietic stem cell transplant recipients: 10,000/L versus 20,000/microL trigger. <i>Biology of Blood and Marrow Transplantation</i> , 2002 , 8, 569-76	4.7	118
106	Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. <i>Biology of Blood and Marrow Transplantation</i> , 2002 , 8, 145-54	4.7	164
105	Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2002 , 8, 122-30	4.7	197
104	Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and Rituximab. <i>Bone Marrow Transplantation</i> , 2001 , 27, 329-32	4.4	21
103	Gastroparesis following bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2001 , 28, 59-62	4.4	38

102	A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 2001 , 28, 187-96	4.4	55
101	Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. <i>Clinical Infectious Diseases</i> , 2001 , 33, 947-53	11.6	217
100	Monitoring vital signs in a bone marrow transplant unit: are they needed in the middle of the night?. <i>Bone Marrow Transplantation</i> , 2001 , 27, 1197-200	4.4	6
99	Caspofungin. <i>Drugs</i> , 2001 , 61, 1130-1131	12.1	
98	Infections following hematopoietic stem cell transplantation. <i>Infectious Disease Clinics of North America</i> , 2001 , 15, 483-520	6.5	46
97	Blood and Marrow Transplantation 2001 , 19-37		1
96	Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. <i>Medicine (United States)</i> , 2000 , 79, 250-60	1.8	574
95	Acquiescence to adjunctive experimental therapies may relate to psychological distress: pilot data from a bone marrow transplant center. <i>Bone Marrow Transplantation</i> , 2000 , 25, 673-6	4.4	5
94	Management of CMV Infections after Bone Marrow Transplantation: A Paradigm Shift. <i>Fetal and Pediatric Pathology</i> , 2000 , 19, 205-220		
93	A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABL Collaborative Study Group. <i>Clinical Infectious Diseases</i> , 2000 , 31, 1155-63	11.6	412
92	Status of high-dose chemotherapy for breast cancer: a review. <i>Biology of Blood and Marrow Transplantation</i> , 2000 , 6, 476-95	4.7	23
91	Evidence-Based Reviews and the Role of Blood and Marrow Transplantation in the Treatment of Selected Diseases: An ASBMT Policy Statement. <i>Biology of Blood and Marrow Transplantation</i> , 2000 , 6, 523-525	4.7	7
90	Characterization and outcome of "hard to mobilize" lymphoma patients undergoing autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2000 , 39, 509-19	1.9	73
89	Subcutaneous phaeohyphomycosis in transplant recipients: review of the literature and demonstration of in vitro synergy between antifungal agents. <i>Medical Mycology</i> , 2000 , 38, 169-175	3.9	6
88	Treatment Results in Aplastic Anemia Trials Need To Be Analyzed Separately for Pediatric and Adult Populations. <i>Blood</i> , 1999 , 94, 1833-1834	2.2	6
87	Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. <i>Clinical Infectious Diseases</i> , 1999 , 29, 1402-7	11.6	288
86	Opportunistic infections after blood and marrow transplantation. <i>Transplant Infectious Disease</i> , 1999 , 1, 3-20	2.7	48
85	High-Dose Chemotherapy with Autologous Stem Cell Rescue as a Treatment Modality for Breast Cancer. <i>Breast Journal</i> , 1999 , 5, 308-318	1.2	1

84	Comparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight. <i>Bone Marrow Transplantation</i> , 1999 , 23, 867-73	4.4	15
83	Practical considerations in the use of tacrolimus for allogeneic marrow transplantation. <i>Bone Marrow Transplantation</i> , 1999 , 24, 1053-6	4.4	44
82	Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation. <i>Bone Marrow Transplantation</i> , 1999 , 24, 1323-7	4.4	23
81	Reintegration after bone marrow transplantation. <i>Cancer Practice</i> , 1999 , 7, 190-7		96
80	Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. <i>New England Journal of Medicine</i> , 1999 , 341, 14-21	59.2	601
79	Fungal infections after bone marrow transplant. <i>Biology of Blood and Marrow Transplantation</i> , 1999 , 5, 55-68	4.7	89
78	Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 1999 , 5, 94-7	4.7	69
77	Tacrolimus vs. cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine. <i>Biology of Blood and Marrow Transplantation</i> , 1999 , 5, 180-6	4.7	30
76	Thalidomide in children undergoing bone marrow transplantation: series at a single institution and review of the literature. <i>Pediatrics</i> , 1999 , 103, e44	7.4	25
75	Can 40 seconds of compassion reduce patient anxiety?. <i>Journal of Clinical Oncology</i> , 1999 , 17, 371-9	2.2	355
74	Stem Cell Collection for Hematopoietic Transplantation: Stem Cell Sources, Mobilization Strategies, and Factors that Influence Yield 1999 , 341-356		
73	Tacrolimus pharmacokinetics in BMT patients. <i>Bone Marrow Transplantation</i> , 1998 , 21, 23-8	4.4	35
72	Successful salvage using mismatched umbilical cord blood transplant in an adult with recurrent acute myelogenous leukemia failing autologous peripheral blood progenitor cell transplant: a case history and review. <i>Bone Marrow Transplantation</i> , 1998 , 21, 1197-200	4.4	7
71	Measurement of absolute concentration and viability of CD34+ cells in cord blood and cord blood products using fluorescent beads and cyanine nucleic acid dyes. <i>Cytometry</i> , 1998 , 34, 121-127		31
70	An open-label dose comparison study of ondansetron for the prevention of emesis associated with chemotherapy prior to bone marrow transplantation. <i>Supportive Care in Cancer</i> , 1998 , 6, 511-7	3.9	9
69	Relationship of tacrolimus (FK506) whole blood concentrations and efficacy and safety after HLA-identical sibling bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 1998 , 4, 157-63	4.7	19
68	Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia. <i>Clinical Infectious Diseases</i> , 1998 , 27, 296-302	11.6	256
67	The effect of overnight storage of leukapheresis stem cell products on cell viability, recovery, and cost. <i>Stem Cells and Development</i> , 1998 , 7, 431-6		17

66	Quality of life following bone marrow transplantation. <i>Current Opinion in Oncology</i> , 1998 , 10, 108-11	4.2	7
65	Efficacy of low-dose dopamine in preventing amphotericin B nephrotoxicity in bone marrow transplant patients and leukemia patients. <i>Antimicrobial Agents and Chemotherapy</i> , 1998 , 42, 3103-6	5.9	19
64	Recent advances in the management of viral infections. <i>Cancer Treatment and Research</i> , 1998 , 96, 183-205	9.5	95
63	Acute oral pain and mucositis in bone marrow transplant and leukemia patients: data from a pilot study. <i>Cancer Nursing</i> , 1998 , 21, 385-93	2.6	49
62	The True Cost of Bone Marrow Transplantation. <i>American Journal of the Medical Sciences</i> , 1997 , 314, 101-112	2.2	1
61	Isolation and characterization of fluconazole- and amphotericin B-resistant <i>Candida albicans</i> from blood of two patients with leukemia. <i>Antimicrobial Agents and Chemotherapy</i> , 1997 , 41, 196-9	5.9	178
60	Successful engraftment after primary graft failure in aplastic anemia using G-CSF mobilized peripheral stem cell transfusions. <i>Bone Marrow Transplantation</i> , 1997 , 19, 175-7	4.4	9
59	Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. <i>Bone Marrow Transplantation</i> , 1997 , 19, 343-7	4.4	69
58	Lack of interaction between tacrolimus (FK506) and methotrexate in bone marrow transplant recipients. <i>Bone Marrow Transplantation</i> , 1997 , 20, 49-51	4.4	7
57	Allogeneic bone marrow transplantation with matched unrelated donors for patients with hematologic malignancies using a preparative regimen of high-dose cyclophosphamide and fractionated total body irradiation. <i>Bone Marrow Transplantation</i> , 1997 , 20, 219-25	4.4	13
56	The true cost of bone marrow transplantation. <i>American Journal of the Medical Sciences</i> , 1997 , 314, 101-112	12	12
55	Host immunologic augmentation for the control of infection. <i>Infectious Disease Clinics of North America</i> , 1996 , 10, 345-64	6.5	1
54	Management of Viral Infections in Bone Marrow Transplant Recipients. <i>BioDrugs</i> , 1996 , 6, 352-382		
53	Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care. <i>Journal of Clinical Oncology</i> , 1996 , 14, 1156-64	2.2	48
52	Coping with the physical and psychosocial sequelae of bone marrow transplantation among long-term survivors. <i>Journal of Behavioral Medicine</i> , 1996 , 19, 163-84	3.6	36
51	Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation. <i>Hepatology</i> , 1996 , 24, 588-91	11.2	90
50	Necrotizing cerebritis in an allogeneic bone marrow transplant recipient due to <i>Cladophialophora bantiana</i> . <i>Journal of Clinical Microbiology</i> , 1996 , 34, 1330-2	9.7	23
49	Evaluation of the drug interaction between intravenous high-dose fluconazole and cyclosporine or tacrolimus in bone marrow transplant patients. <i>Transplantation</i> , 1996 , 61, 1268-72	1.8	67

48	Diagnosis and therapeutic monitoring of invasive candidiasis by rapid enzymatic detection of serum D-arabinitol. <i>American Journal of Medicine</i> , 1995 , 99, 164-72	2.4	75
47	Importance of <i>Candida</i> species other than <i>C. albicans</i> as pathogens in oncology patients. <i>Clinical Infectious Diseases</i> , 1995 , 20, 115-25	11.6	410
46	Sinusitis in the Bone Marrow Transplant Patient: Diagnosis and Management. <i>American Journal of Rhinology & Allergy</i> , 1995 , 9, 31-36		1
45	Randomized trial of loperamide versus dose escalation of octreotide acetate for chemotherapy-induced diarrhea in bone marrow transplant and leukemia patients. <i>American Journal of Hematology</i> , 1995 , 50, 167-72	7.1	21
44	Early detection of human cytomegalovirus viremia in bone marrow transplant recipients by DNA amplification. <i>Journal of Clinical Microbiology</i> , 1995 , 33, 1263-6	9.7	30
43	Infections due to resistant <i>Candida</i> species in patients with cancer who are receiving chemotherapy. <i>Clinical Infectious Diseases</i> , 1994 , 19 Suppl 1, S49-53	11.6	70
42	Viral infections in severely immunocompromised cancer patients. <i>Supportive Care in Cancer</i> , 1994 , 2, 355-68	3.9	19
41	Predictors of acute respiratory failure after bone marrow transplantation in children. <i>Critical Care Medicine</i> , 1994 , 22, 1485-91	1.4	115
40	Changes in the Spectrum of Fungal Infections in Bone Marrow Transplant Patients. <i>Infectious Diseases in Clinical Practice</i> , 1994 , 3, S83-S89	0.2	4
39	Chromosome abnormalities in patients treated with 4-hydroperoxycyclophosphamide-purged autologous bone marrow transplantation. <i>Cancer Genetics and Cytogenetics</i> , 1993 , 65, 135-40		3
38	Association of <i>Torulopsis glabrata</i> infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients. <i>Antimicrobial Agents and Chemotherapy</i> , 1993 , 37, 1847-9	5.9	287
37	Loss and Recovery Themes of Long-Term Survivors of Bone Marrow Transplants. <i>Journal of Psychosocial Oncology</i> , 1993 , 10, 1-20	2.8	43
36	Personal changes, dispositional optimism, and psychological adjustment to bone marrow transplantation. <i>Journal of Behavioral Medicine</i> , 1993 , 16, 423-43	3.6	166
35	The use of fluconazole prophylaxis in patients with chemotherapy-induced neutropenia. <i>Leukemia and Lymphoma</i> , 1992 , 8, 353-9	1.9	10
34	Development of the Satisfaction with Life Domains Scale for Cancer. <i>Journal of Psychosocial Oncology</i> , 1992 , 10, 75-90	2.8	34
33	Thalidomide for the treatment of chronic graft-versus-host disease. <i>New England Journal of Medicine</i> , 1992 , 326, 1055-8	59.2	360
32	Bone marrow transplantation of chronic myelogenous leukemia in chronic phase: evaluation of risks and benefits. <i>Journal of Clinical Oncology</i> , 1992 , 10, 779-89	2.2	38
31	Oral mucositis after bone marrow transplantation. A marker of treatment toxicity and predictor of hepatic veno-occlusive disease. <i>Oral Surgery, Oral Medicine, and Oral Pathology</i> , 1991 , 72, 419-24		27

30	Role retention and quality of life of bone marrow transplant survivors. <i>Social Science and Medicine</i> , 1991 , 32, 697-704	5.1	73
29	Optic disc edema after bone marrow transplantation. Possible role of cyclosporine toxicity. <i>Ophthalmology</i> , 1991 , 98, 1294-301	7.3	62
28	Increase in <i>Candida krusei</i> infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. <i>New England Journal of Medicine</i> , 1991 , 325, 1274-7	59.2	820
27	Health, functional status, and employment of adult survivors of bone marrow transplantation. <i>Annals of Internal Medicine</i> , 1991 , 114, 113-8	8	112
26	Orthotopic liver transplantation for graft-versus-host disease following bone marrow transplantation. <i>Gastroenterology</i> , 1990 , 99, 536-8	13.3	36
25	Allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia. <i>Journal of Clinical Oncology</i> , 1990 , 8, 820-30	2.2	72
24	Cytomegalovirus infections in bone marrow transplant recipients given intensive cytoreductive therapy. <i>Clinical Infectious Diseases</i> , 1990 , 12 Suppl 7, S793-804	11.6	53
23	Herpesvirus and enteric viral infections in bone marrow transplantation: clinical presentations, pathogenesis, and therapeutic strategies. <i>Cancer Investigation</i> , 1990 , 8, 509-21	2.1	13
22	Coaggregation of oral <i>Candida</i> isolates with bacteria from bone marrow transplant recipients. <i>Journal of Clinical Microbiology</i> , 1990 , 28, 2621-6	9.7	30
21	Longitudinal changes in pulmonary function following bone marrow transplantation. <i>Chest</i> , 1989 , 96, 301-6	5.3	46
20	Cutaneous graft-versus-host reaction lacks evidence of cutaneous cytomegalovirus by the immunoperoxidase technique. <i>Journal of Investigative Dermatology</i> , 1989 , 93, 92-5	4.3	5
19	Interstitial pneumonitis after allogeneic bone marrow transplantation. Nine-year experience at a single institution. <i>Medicine (United States)</i> , 1988 , 67, 175-86	1.8	131
18	Interstitial pneumonitis following autologous bone marrow transplantation. <i>Transplantation</i> , 1988 , 46, 61-5	1.8	53
17	Successful marrow transplantation for acute myelocytic leukemia following therapy for Hodgkin's disease. <i>Journal of Clinical Oncology</i> , 1988 , 6, 1558-61	2.2	32
16	Prevention of fungal sepsis in patients with prolonged neutropenia: a randomized, double-blind, placebo-controlled trial of intravenous miconazole. <i>American Journal of Medicine</i> , 1987 , 83, 1103-10	2.4	81
15	Differences between first and subsequent fevers during prolonged neutropenia. <i>Cancer</i> , 1987 , 59, 844-96.4	16	
14	Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. <i>New England Journal of Medicine</i> , 1986 , 315, 141-7	59.2	313
13	Antibiotic-resistant bacteria in surveillance stool cultures of patients with prolonged neutropenia. <i>Antimicrobial Agents and Chemotherapy</i> , 1986 , 30, 435-9	5.9	30

12	Detection of Epstein-Barr virus DNA in mouthwashes by hybridization. <i>Journal of Clinical Microbiology</i> , 1985 , 21, 353-6	9.7	28
11	Genetic analysis of the susceptibility of mouse cytomegalovirus to acyclovir. <i>Journal of Virology</i> , 1985 , 54, 104-13	6.6	11
10	Effect of several antiviral agents on human lymphocyte functions and marrow progenitor cell proliferation. <i>Antimicrobial Agents and Chemotherapy</i> , 1983 , 23, 593-7	5.9	24
9	Acyclovir in mouse cytomegalovirus infections. <i>American Journal of Medicine</i> , 1982 , 73, 118-24	2.4	11
8	Differences in virulence of clinical isolates of <i>Candida tropicalis</i> and <i>Candida albicans</i> in mice. <i>Infection and Immunity</i> , 1982 , 37, 833-6	3.7	57
7	Activity of trifluorothymidine against cytomegalovirus. <i>Antimicrobial Agents and Chemotherapy</i> , 1981 , 20, 286-90	5.9	25
6	Efficacy of acyclovir against mouse cytomegalovirus in vivo. <i>Antimicrobial Agents and Chemotherapy</i> , 1981 , 20, 275-8	5.9	14
5	Thymidine kinase not required for antiviral activity of acyclovir against mouse cytomegalovirus. <i>Journal of Virology</i> , 1981 , 39, 889-93	6.6	38
4	The value of fungal surveillance cultures as predictors of systemic fungal infections. <i>Journal of Infectious Diseases</i> , 1980 , 142, 503-9	7	193
3	<i>Candida tropicalis</i> : a major pathogen in immunocompromised patients. <i>Annals of Internal Medicine</i> , 1979 , 91, 539-43	8	209
2	Prevention and Treatment of Fungal Infections in Hematopoietic Cell Transplants152-162		
1	Seasonal Virus Infections: Prevention and Management Guidelines116-129		